

and nonusers. Outcome was evaluated through urine controls, considering a poor outcome when positive to heroin > 20%.

Results Of the 76 patients in MMT, the average age was 40 years, 21% were women, mean dosage of methadone was 48.2 mg/day and more than a half were DCR users (52.63%). Of the 40 patients, which formed the DCR user subgroup, the average age was 36.4 years, 20% were women and mean dosage of methadone was 47 mg/day. The outcome of all the patients in PMM was successful in 48.68% of the cases, presenting differentially the nonusers a 91.67% of good response and the users only a 10%.

Conclusions Inclusion of a drug consumption room in an outpatient treatment center for alcoholism and drug abuse, which facilitates accessibility for people who inject drugs to treatment, poses new challenges in order to improve the effectiveness of the PMM.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.02.451>

EW0838

U-47700: The new emerging opioid drug

D. Sanagustin Bosqued*, M. De Dios Felis, E. Monteagudo Gimeno, S. Pérez González, A. Trabsa Biskri, L. Galindo Guarín, M. Grifell Guardia, P. Quintana Mathe, M. Torrens Melich

Institut de Neuropsiquiatria i Adiccions, Psychiatry, Barcelona, Spain

* Corresponding author.

Introduction The trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) labelled as U-47700 has a high affinity with the selective receptor, considered to have 7.5 times the binding affinity of morphine; as a result, it is sold as a recreational drug because of its analgesic and euphoric effects. Several toxicity cases and some fatalities have been reported during 2016.

Objectives To describe the presence of trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) in samples delivered to Energy Control during 2016 in Barcelona.

Methods From January 2016 to October 2016, 4031 samples were delivered and only those samples containing trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl) were studied, 6 of them were analysed as U-47700 (0.148%). Samples were analysed by energy control, a Spanish harm-reduction NGO that offers users the possibility of analysing the substances they intend to consume. Analysis was done by gas chromatography–mass spectrometry.

Results From the 6 samples that were analysed as trans-3;4-dichloro-N-(2-(dimethylamine) cyclohexyl), the presentation of 4 of them was white powder and the rest were not described. The precedence of the samples was Canada (2), USA (1), Sweden (1), Holland (1) and the remaining sample was not described. All samples were received during 2016.

Conclusions The use of trans-3;4-dichloro-N-(2-(dimethylamine)cyclohexyl) is progressively increasing in Barcelona. Its harmful effects are being reported in recent medical literature and consumption represents an emerging issue, gaining popularity among recreational opioid users. It is potentially lethal when mixed with depressants like alcohol or benzodiazepines and overdose risk is higher compared to other opioids. This drug is not being detected by routine in medical test.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.02.452>

EW0839

Substance use and quality of life in young adult psychiatric patients

J. Silva Ribeiro*, S. Morais, P. Oliveira, O. Mendes, A. Botelho, L. Vale, A. Bessa, P. Renca, V. Santos, N. Madeira
Centro Hospitalar e Universitário de Coimbra, Centro de Responsabilidade Integrado de Psiquiatria e Saúde Mental, Coimbra, Portugal

* Corresponding author.

Introduction It is known that several factors can influence the quality of life such as age, gender, socioeconomic status, the presence of mental illness or substance abuse.

Objectives/aims Assess quality of life of outpatients observed in Young Adult Unit of our Psychiatry Department (Coimbra Hospital and University Centre – Portugal) and its relation with substance use.

Methods Socio-demographic characterization of youth psychiatric outpatients observed during between 1st January 2015 and 31st July 2016. Portuguese versions of The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and The World Health Organization Quality of Life scale (WHOQOL-BREF) were administered. A Spearman correlation coefficient between ASSIST and WHOQOL-BREF scores was calculated.

Results A total of 255 outpatients were observed: 64.3% females and 35.7% males; ages between 17 and 39 years old. ASSIST and WHOQOL-BREF were administered in 57 patients. Average ASSIST total score was 16.81 (median: 13.50), with tobacco and alcohol scoring higher. Average WHOQOL-BREF total was 13.74 (median: 13.67), with physical and psychological domains scoring less. We found a significant negative correlation between WHOQOL-BREF physical domain and ASSIST tobacco scores; and between WHOQOL-BREF social domain and ASSIST sedatives score.

Conclusions Quality of life is influenced by several factors. Studies showed that consumers of psychoactive substances have lower WHOQOL-BREF scores than nonusers. In our sample, we did not find a significant correlation between global quality of life and different substances. This may be due to existence of low consumption of substances in the sample as well as the existence of other factors that might have influenced quality of life.

Disclosure of interest The authors have not supplied their declaration of competing interest.

<http://dx.doi.org/10.1016/j.eurpsy.2017.02.453>

EW0840

Efficiency of Cocarnit preparation in clinical course of alcohol dependence at withdrawal syndrome stage

I. Sosin^{1,*}, O. Goncharova², Y. Chuev²

¹ *Kharkov Medical Academy of Postgraduate Education, Narcology, Kharkov, Ukraine*

² *Kharkiv Medical Academy of Postgraduate Education, Narcology, Kharkiv, Ukraine*

* Corresponding author.

Introduction Recently scientific attention of Ukrainian narcology was focused on the group of new complex pharmacological preparations with polymodal pathogenic effect option (Cocarnit, World Medicine, Great Britain).

Aims and objectives To ground feasibility of Cocarnit application in complex treatment of alcohol withdrawal syndrome (AWS).

Method Eleven patients with alcohol addiction were examined. An integrated research of relieving and adjuvant effects of pharmacological preparation Cocarnit in complex with traditional detoxication therapy in clinical course of alcohol dependence at AWS stage was carried out. One to 2 ampoules of Cocarnit were injected intramuscularly once per 24 hrs, № 6.